AMIX
Autonomix MedicalAMIX
AMIX
About: Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
Employees: 11
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5.8% less ownership
Funds ownership: 12.07% [Q4 2024] → 6.26% (-5.8%) [Q1 2025]
7% less funds holding
Funds holding: 14 [Q4 2024] → 13 (-1) [Q1 2025]
70% less capital invested
Capital invested by funds: $477K [Q4 2024] → $144K (-$332K) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
285%
upside
Avg. target
$5
285%
upside
High target
$5
285%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Anthony Vendetti | 285%upside $5 | Buy Initiated | 29 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix's strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025.
Positive
Zacks Investment Research
3 weeks ago
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics
Neutral
GlobeNewsWire
1 month ago
Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET
Neutral
GlobeNewsWire
1 month ago
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here
Neutral
GlobeNewsWire
1 month ago
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up Company has initiated market expansion study (“PoC 2”) of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025 Additional indications potentially double the addressable market beyond pancreatic cancer pain THE WOODLANDS, TX, April 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided an update on the initial trial phase of its first-in-human proof-of-concept trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. The Company enrolled twenty (20) patients in PoC 1, including the first five (5) “lead-in” patients.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France.
Neutral
GlobeNewsWire
1 month ago
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix's Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company's common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual's employment compensation and was granted as an inducement material to their start of employment with the Company.
Charts implemented using Lightweight Charts™